Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Incretin-Based Therapies: Revisiting Their Mode of Action.

Literature DB >> 28575434

Incretin-Based Therapies: Revisiting Their Mode of Action.

Brian T Layden^1,2, Barton Wicksteed¹, Franck Mauvais-Jarvis³.

Abstract

Mesh：

Substances：

Year: 2017 PMID： 28575434 PMCID： PMC5460946 DOI： 10.1210/en.2017-00252

Source DB: PubMed Journal: Endocrinology ISSN： 0013-7227 Impact factor: 4.736

Keyword Cloud
References

× No keyword cloud information.

28 in total

Review 1. GPCR desensitization: Acute and prolonged phases.

Authors: Sudarshan Rajagopal; Sudha K Shenoy
Journal: Cell Signal Date: 2017-01-28 Impact factor: 4.315

2. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.

Authors: Matteo Monami; Besmir Nreu; Alessia Scatena; Barbara Cresci; Francesco Andreozzi; Giorgio Sesti; Edoardo Mannucci
Journal: Diabetes Obes Metab Date: 2017-06-20 Impact factor: 6.577

Review 3. Minireview: Novel aspects of M3 muscarinic receptor signaling in pancreatic β-cells.

Authors: Kenichiro Nakajima; Shalini Jain; Inigo Ruiz de Azua; Sara M McMillin; Mario Rossi; Jürgen Wess
Journal: Mol Endocrinol Date: 2013-07-02

4. Galphaz negatively regulates insulin secretion and glucose clearance.

Authors: Michelle E Kimple; Jamie W Joseph; Candice L Bailey; Patrick T Fueger; Ian A Hendry; Christopher B Newgard; Patrick J Casey
Journal: J Biol Chem Date: 2007-12-20 Impact factor: 5.157

Review 5. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.

Authors: Abd A Tahrani; Anthony H Barnett; Clifford J Bailey
Journal: Nat Rev Endocrinol Date: 2016-06-24 Impact factor: 43.330

6. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.

Authors: Belinda Gier; Aleksey V Matveyenko; David Kirakossian; David Dawson; Sarah M Dry; Peter C Butler
Journal: Diabetes Date: 2012-01-20 Impact factor: 9.461

Incretin-Based Therapies: Revisiting Their Mode of Action.

Review 1. GPCR desensitization: Acute and prolonged phases.

2. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.

Review 3. Minireview: Novel aspects of M3 muscarinic receptor signaling in pancreatic β-cells.

4. Galphaz negatively regulates insulin secretion and glucose clearance.

Review 5. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.

6. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.

Review 7. Human β-cell proliferation and intracellular signaling: part 3.

Review 8. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.

Review 9. Human β-cell proliferation and intracellular signaling part 2: still driving in the dark without a road map.

10. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.